Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) reported $0.5M Q4 revenue and $2.0M for 2025, including $1.4M of Symvess sales. The company received a $1.475M purchase commitment in Saudi Arabia, submitted a Marketing Authorization Application in Israel, and secured DoD funding support.
Key milestones: top-line interim result from the V012 Phase 3 hemodialysis study expected by early June 2026 and planned BLA filing in H2 2026. Cash was $50.5M at year-end, with subsequent equity proceeds and a $40M initial tranche from a $77.5M credit facility.
Humacyte (Nasdaq: HUMA) appointed Rick McElheny as Senior Vice President of Business Development effective March 26, 2026. McElheny brings more than 15 years of corporate development and alliance management experience and will lead efforts to expand collaborations to commercialize Humacyte’s bioengineered tissue pipeline.
His prior roles include SVP of Corporate Development at Clearside and founder/VP of corporate development at Vidara, where he led transactions including a $660 million sale and over $250 million in out‑licensing deals.
Humacyte (Nasdaq: HUMA) will release fourth quarter and year‑end financial results for the period ended December 31, 2025 on March 27, 2026, and will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
The company emphasizes its commercial‑stage biotechnology platform and notes FDA approval of Symvess (ATEV) for vascular trauma in December 2024 and ongoing late‑stage trials in AV access and PAD.
Humacyte (Nasdaq: HUMA) received a binding minimum purchase commitment of $1.475 million for Symvess to support a clinical evaluation and outreach program in hospitals in the Kingdom of Saudi Arabia (KSA), announced March 19, 2026.
Humacyte will provide training personnel, will not negotiate commercialization rights in the KSA with other parties through July 2, 2026, and is negotiating a potential joint venture and license to commercialize Symvess in the KSA. Symvess remains investigational for uses beyond its FDA-approved extremity vascular trauma indication.
Humacyte (Nasdaq: HUMA) entered a registered direct offering to sell 25,000,000 shares, expected to raise gross proceeds of $20.0 million, with closing on or about March 20, 2026.
Proceeds are intended to fund commercialization of Symvess for vascular trauma, a BLA supplement filing and the upcoming Phase 3 hemodialysis read-out, pipeline development, and general corporate purposes.
Humacyte (Nasdaq: HUMA) submitted a Marketing Authorization Application (MAA) to the Israel Ministry of Health for Symvess, its acellular tissue engineered vessel for extremity arterial trauma repair, on March 17, 2026.
Humacyte is also pursuing hospital-by-hospital access in Israel before approval and plans broader Middle East expansion; clinical data cited include a retrospective 16-patient wartime series with 100% survival, zero amputations and zero conduit infections.
Humacyte (Nasdaq: HUMA) said its management team will participate in investor conferences in March 2026. Presentations are scheduled at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026 at 10:30–11:00 AM ET and a Barclays 28th Annual Global Healthcare fireside chat at 1:00–1:25 PM ET. Both sessions will be available via webcast.
Humacyte (Nasdaq: HUMA) presented 36-month V005 trial results for Symvess at the VESS Annual Winter Meeting on Feb 18, 2026. Symvess showed 92.9% infection-free rate from months 3–36, 87.3% limb salvage at 12 months and durable vessel diameter with no dilatation or narrowing through 36 months.
No conduit-related deaths or spontaneous structural failures were reported; three conduit infections occurred overall.
Humacyte (Nasdaq: HUMA) said the FY2026 U.S. Department of Defense appropriations include targeted funding to support procurement and evaluation of biologic vascular repair technologies for traumatic extremity arterial injuries when autologous vein grafting is not feasible.
Symvess is described as the only human-derived bioengineered blood vessel approved by the FDA; the release highlights a retrospective battlefield study of 16 patients with 100% survival, zero amputations, and zero conduit infections. Safety risks, including graft rupture, anastomotic failure, and thrombosis, are noted with boxed warning language and recommended antiplatelet therapy.
Humacyte (Nasdaq: HUMA) released a five-year retrospective analysis of hospital charges and payer costs for extremity arterial injury (2018–2023). The average initial hospital charge was $316,600 per patient; graft infection and amputation raised charges by about $589,921 and $492,986, respectively, while average reimbursed costs were far lower ($84,598 for infection, $116,611 for amputation). 26% of repairs used conduits other than autologous vein. Humacyte highlights Symvess as an off-the-shelf biologic conduit with markedly lower infection and amputation rates versus historical controls and reports positive three-year V005 Phase 2/3 results supporting limb salvage benefits.